Zobrazeno 1 - 10
of 2 861
pro vyhledávání: '"macular oedema"'
Publikováno v:
TNOA Journal of Ophthalmic Science and Research, Vol 62, Iss 2, Pp 173-179 (2024)
Background: Diabetes mellitus (DM) is a major health hazard today. Clinically significant macular oedema (CSME) is the most frequent cause of decreased vision in diabetic patients. The aim of our study was to determine whether CSME in subjects with t
Externí odkaz:
https://doaj.org/article/99761f95ffbf46ef82eeb4a985245f2e
Autor:
Tara Li, Vladislav Berdunov, Robin Hamilton, Yaneth Gil Rojas, Christian Bührer, Oliver Cox, Roelien Postema, Marloes Bagijn
Publikováno v:
Ophthalmology and Therapy, Vol 13, Iss 10, Pp 2577-2597 (2024)
Abstract Introduction Cost-effectiveness analyses typically ignore healthcare system resource constraints. Ophthalmology is affected by resource constraints because of increasing disease prevalence and the use of resource-intensive treatments. This s
Externí odkaz:
https://doaj.org/article/2f0af42837ee4e47b16942b6be2fd37b
Publikováno v:
Ophthalmology and Therapy, Vol 13, Iss 8, Pp 2063-2066 (2024)
Abstract This is a summary of the original article ‟Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis”. DMO, a serious eye condition that can lead to vision loss in people with diabetes, is a signi
Externí odkaz:
https://doaj.org/article/03c2c0b0de9f45fd8c4175f89e79f956
Autor:
Benjamin Abaidoo, Alec Bernard, Jessica A. Sedhom, Andrew E. Akafo, Patience Yeboah, Shannan Berzack, Ashiyana Nariani, Imoro Zeba Braimah
Publikováno v:
African Vision and Eye Health, Vol 83, Iss 1, Pp e1-e6 (2024)
Background: Accurate and objective diagnosis of centre-involving diabetic macular oedema (ci-DMO) requires the use of optical coherence tomography (OCT). There is limited data on the availability and rate of utilisation of OCT for the management of D
Externí odkaz:
https://doaj.org/article/7669f76f772d4d00ad019f8dfcac93bf
Autor:
Reham Abdelraouf Abdellatif Khalil, Ahmed Hassan Aldghaimy, Wael Elshazly Eida, Ahmed Ali Ahmed Amer
Publikováno v:
SVU - International Journal of Medical Sciences, Vol 7, Iss 1, Pp 746-752 (2024)
Background: Diabetes mellitus, or DM, is a condition that increases the risk of developing cataracts. Cataracts are one of the leading causes of blindness; some studies report that DM patients with cataracts have an increased risk of progression, whi
Externí odkaz:
https://doaj.org/article/75952c7a953948b79995a49812650a04
Publikováno v:
TNOA Journal of Ophthalmic Science and Research, Vol 62, Iss 1, Pp 48-54 (2024)
Aim: To study the incidence of central macular oedema at 4, 8 and 12 weeks following cataract surgery in diabetic retinopathy eyes. Materials and Methods: A prospective observational study was conducted over a period of 3 months to investigate the pr
Externí odkaz:
https://doaj.org/article/0598908ab3bd4b008c1660b633e71c22
Autor:
Amir Ramadan Gomaa, Ahmed Magdy Bedda, Hesham Fouad ElGoweini, Raghda Saad Zaghloul Taleb, Ahmed Mahmoud Abdelrahman Saleh
Publikováno v:
BMC Ophthalmology, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background The aim was to study aqueous humour inflammatory mediators’ levels in a cohort of Egyptian patients with diabetic macular oedema (DMO). Methods This was a case-control prospective study conducted on 2 groups: 25 eyes of 22 (11 f
Externí odkaz:
https://doaj.org/article/c6f5198d9e634bb7a04bbf11673a7b01
Publikováno v:
Systematic Reviews, Vol 12, Iss 1, Pp 1-12 (2023)
Abstract Background Different network meta-analyses (NMAs) on the same topic result in differences in findings. In this review, we investigated NMAs comparing aflibercept with ranibizumab for diabetic macular oedema (DME) in the hope of illuminating
Externí odkaz:
https://doaj.org/article/393f24b508d2468fb2388526d9784437
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 17, Pp 2861-2873 (2023)
Georgios D Panos,1,2 Arun Lakshmanan,1 Panagiotis Dadoukis,3 Matteo Ripa,4 Lorenzo Motta,4 Winfried M Amoaku1,2 1Department of Ophthalmology, Queen’s Medical Centre, Nottingham University Hospitals, Nottingham, UK; 2Division of Ophthalmology and Vi
Externí odkaz:
https://doaj.org/article/c096be889840499e94ffbc0a0de8550e
Publikováno v:
Ophthalmology and Therapy, Vol 12, Iss 5, Pp 2253-2264 (2023)
Abstract Introduction This review aims to assess the efficacy, durability and safety of faricimab—a dual vascular endothelial growth factor and angiopoietin 2 inhibitor—in patients with neovascular age-related macular degeneration (nAMD) and diab
Externí odkaz:
https://doaj.org/article/e2b8a4168e174412896b6966dfb04925